Emend Medicare coverage
Executive Summary
CMS is developing a national coverage determination for Merck's anti-emetic Emend and will accept public comment until Aug. 6, agency says July 6. CMS "internally generated a national coverage determination to determine if aprepitant is full replacement for other covered treatment(s) for chemotherapy-induced emesis," agency said. "If aprepitant is determined to be full replacement, CMS will then describe the circumstances where it is reasonable and necessary for Medicare beneficiaries." CMS' targeted completion date for the NCD is April 1, 2005...
You may also be interested in...
Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche
Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.